DAYTONA BEACH, FL--(Marketwired - Apr 2, 2013) - Quture International, Inc. (OTCQB: QUTR) announced today that real-time clinical data was recently collected for approximately 800 perioperative patients at the University of Miami/Jackson Memorial Hospital (UoM). Keith A. Candiotti, MD, and his physician and clinical team and information technology experts collaborated to complete the formal Clinical Trial with Quture under contract, strict protocol supervised by the Investigational Review Board (IRB) and assisted by InterSystems Corporation, Cambridge, MA.
Quture announced the satisfactory completion of the Demonstration Project at UoM for a proof of concept and statement of work for use of the InterSystems technology on September 6, 2011. This phase of the clinical trial was to demonstrate the success of the InterSystems tools of the Ensemble interface engine, Cache object-oriented database, DeepSee data display and Zen report writer as the embedded technology of its QualOptima. QualOptima is Quture's "transformative and disruptive" tool to enhance clinical performance to achieve optimal patient outcomes, with this phase of the project at UoM using a sample/test database.
Successful completion of the Clinical Trial used QualOptima with patient care to analyze the value proposition of the product to hospitals and physicians, as well as payers, regulators, suppliers and consumers of health care.
"Quture has carefully completed data collection and now analysis just in time to support marketing and sales of QualOptima under the brilliant mentoring of Dr. Candiotti and his team," said Landon Feazell, CEO of Quture International. "As we enter competition with companies whose performance and outcomes analytics experience and expertise is rooted in analyzing claims and administrative data, this Clinical Trial proves and differentiates our product collecting real-time clinical data. The University of Miami/Jackson Memorial product experience positions us in the analytics market consistent with our product and marketing strategy for the future to transform the payment and delivery systems."
The Clinical Trial and academic study was designed by Candiotti, Executive Vice-Chair & Chief Operating Officer, and Vice-Chair, Clinical Research, Department of Anesthesiology, Jackson Memorial Hospital and University of Miami Miller Medical School, and his team of experts working with Quture and InterSystems. The study connects individual patient risk factors with evidence-based perioperative performance measures compared to patient outcomes. The impact of compliance on outcomes and costs associated with extended stays and complications in recovery and beyond for well-established performance measures in anesthesia connects clinical quality with outcomes and costs. The potential of the product is being evaluated for predictive modeling and developing clinical decision support systems, as well.
Quture met with InterSystems at HIMSS in New Orleans recently on advancing QualOptima using the latest InterSystems technology and adding additional tools for Active Analytics as part of DeepSee. The combined analytics technology of QualOptima is now being applied to the clinical trial data set. Under contract with the University of Miami and Jackson Memorial Hospital, the final results will be announced by them in cooperation with Quture. Formal presentation of the results will be published by Dr. Candiotti, as well as presented at the National Healthcare Performance and Outcomes Summit in Washington, D.C., September 16-18, 2013 (http://www.performanceanalyticssummit.com). Feazell is also the Co-Chairman of the Summit, and Quture is a founding sponsor.
"Quture has now proven the scientific relationship to connect true clinical quality with value," said Feazell. "We are taking lessons learned from over 35 years of measuring clinical performance manually and converting that process and content into an electronic system that provides real-time clinical knowledge and insight for doctors, nurses and hospitals as never before. Our years of developing clinical content and utilizing a new technology platform will finally achieve its potential. This is a significant milestone in the evolution of Quture. Completion of this Clinical Trial, combined with the data collected and analyzed at Niagara Falls Memorial Medical Center, puts us very close to major announcements with InterSystems."
ABOUT QUTURE INTERNATIONAL, INC. (www.quture.com)
Quture International, Inc. (QUTR) is the proven and experienced clinical performance and outcomes analytics company in the United States. The vision of Quture is to connect all constituents in the global health and health care community to clinically and financially focused and sound data transformed through analytics to knowledge that empowers data-driven decisions for results-driven success. As a "Breakthrough" Application Partner of InterSystems Corporation, Quture's technology for capturing, integrating and aggregating data on the InterSystems Enterprise platform is unequalled. The Company's unique product QualOptima develops a second generation CLINICAL database implementing Quture's core competence of clinical content with evidence-based metrics developed for more than 35 years. QualOptima empowers clinical performance enhancement to achieve optimal patient outcomes. Quture's brand is centered on the value proposition of trust, transparency and independence. As the free enterprise solution to improving health and healthcare while reducing costs, Quture is positioned to become the leading clinical knowledge company in the world. Quture International is a Nevada corporation trading under the symbol QUTR.
This release contains forward-looking statements, including, without limitation, statements concerning our business and possible or assumed future results of operations. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons including: our ability to continue as a going concern, adverse economic changes affecting markets we serve; competition in our markets and industry segments; our timing and the profitability of entering new markets; greater than expected costs, customer acceptance of our products or difficulties related to our integration of the businesses we may acquire; and other risks and uncertainties as may be detailed from time to time in our public announcements and SEC filings. Although we believe the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and our future results, levels of activity, performance or achievements may not meet these expectations. We do not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in our expectations, except as required by law. There is no assurance that a definitive agreement will be completed.